Haleon nabs finance chief from Tate & Lyle as CFO steps down.


The chief financial officer of consumer health company Haleon is to step down after three years and will be replaced by Tate & Lyle's CFO Dawn Allen.

  • Haleon
  • 24 April 2024 07:56:21

Source: Sharecast

The company, known for brands like Sensodyne, Centrum and Panadol, announced on Wednesday that Tobias Hestler has decided to leave "to better balance work demands with the management of a long-term health condition".

He will leave the company in November, having served nearly three years after joining in December 2021.

Hestler will be succeeded by Dawn Allen, the current CFO at Tate & Lyle and former CFO at Mars Inc, who also serves on the board at ITV.

Allen, who will receive an annual salary of £730,000 along with an annual bonus and long-term incentive plans, has "extensive consumer and international experience and will be a great addition to our executive team", said Haleon's chief executive Brian McNamara.

Allen said she was "very excited" to join Haleon. "Its clear purpose and fascinating journey through separation and beyond sets a strong foundation for the future. I am looking forward to help shape the next phase of the journey," she said.

In a separate statement, ingredients group Tate & Lyle said: "The board has begun a process to appoint a successor to Mrs Allen and a further announcement will be made in due course."


ISIN: GB00BP92CJ43
Exchange: London Stock Exchange
Sell:
616.00 p
Buy:
482.00 p
Change: -1.50 ( -0.28 %)
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.